关键信息
-
基因名
UGT1A9
- 应用
-
别名
UGT1A9; GNT1; UGT1; UDP-glucuronosyltransferase 1A9; UGT1A9; UDP-glucuronosyltransferase 1-9; UDPGT 1-9; UGT1*9; UGT1-09; UGT1.9; UDP-glucuronosyltransferase 1-I; UGT-1I; UGT1I; lugP4
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O60656
-
表达区间
1-530 aa
-
氨基酸序列
MACTGWTSPLPLCVCLLLTCGFAEAGKLLVVPMDGSHWFTMRSVVEKLILRGHEVVVVMPEVSWQLGRSLNCTVKTYSTSYTLEDLDREFKAFAHAQWKAQVRSIYSLLMGSYNDIFDLFFSNCRSLFKDKKLVEYLKESSFDAVFLDPFDNCGLIVAKYFSLPSVVFARGILCHYLEEGAQCPAPLSYVPRILLGFSDAMTFKERVRNHIMHLEEHLLCHRFFKNALEIASEILQTPVTEYDLYSHTSIWLLRTDFVLDYPKPVMPNMIFIGGINCHQGKPLPMEFEAYINASGEHGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH
-
分子量
86.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
UGT1A9 (UDP-glucuronosyltransferase 1A9) is an important enzyme belonging to the UGT superfamily, primarily involved in the metabolism of various endogenous and exogenous compounds through glucuronidation, a process that facilitates drug elimination and detoxification. Research into UGT1A9 has gained significant traction due to its role in the pharmacokinetics of numerous therapeutic drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs) and certain chemotherapeutics. Given that genetic polymorphisms in the UGT1A9 gene can result in considerable interindividual variability in drug metabolism and response, understanding its functional characteristics is crucial for personalized medicine. The production and characterization of recombinant UGT1A9 proteins allow for detailed studies of enzyme kinetics, substrate specificity, and interaction with inhibitors or inducers, providing essential insights into its role in drug metabolism. Recent advances in molecular biology techniques, such as site-directed mutagenesis and high-throughput screening, have further facilitated the exploration of UGT1A9's enzymatic properties. This research not only helps elucidate the mechanisms of drug metabolism but also aids in the development of more effective therapeutic strategies and the prediction of adverse drug reactions based on genetic profiles. Thus, the study of UGT1A9 and its recombinant protein is of paramount importance in the fields of pharmacology, toxicology, and personalized medicine, aiming to improve drug safety and efficacy for diverse patient populations.
